EPBU lack of samples

Quote

Anonymous

Guest
We were just informed that we will not receive Dulera samples until 2014. Now that Dulera has been moved to 2nd position, it is crucial that we have these samples. I have already been stretching my Asmanex samples(and Nasonex) to last between shipments. This is not good for business and it feels like that they are setting us up to fail.
 






Anonymous said:
We were just informed that we will not receive Dulera samples until 2014. Now that Dulera has been moved to 2nd position, it is crucial that we have these samples. I have already been stretching my Asmanex samples(and Nasonex) to last between shipments. This is not good for business and it feels like that they are setting us up to fail.
Click to expand...

They aren't setting the EPBU to fail. This is simply a part in a series of steps to wind down the contract. Merck is shifting business plans and, while the EPBU was originally part of it, recent events at Merck has caused it to re-evaluate those plans. It may seem hard to believe, but things are winding down for this contract. Merck has already shut down two divisions internally and while it may seem plausible to keep a contract salesforce, there is a very strong opposition to it amongst the powers that be for reasons I cannot disclose here.
 






Anonymous said:
They aren't setting the EPBU to fail. This is simply a part in a series of steps to wind down the contract. Merck is shifting business plans and, while the EPBU was originally part of it, recent events at Merck has caused it to re-evaluate those plans. It may seem hard to believe, but things are winding down for this contract. Merck has already shut down two divisions internally and while it may seem plausible to keep a contract salesforce, there is a very strong opposition to it amongst the powers that be for reasons I cannot disclose here.
Click to expand...

Thank you for your response. There is Information in your post I can definitely confirm. How much time do you think we have left?
 












Anonymous said:
Thank you for your response. There is Information in your post I can definitely confirm. How much time do you think we have left?
Click to expand...

Hi, I was the person who posted the reply last night. According to my sources, the contract is secure to the end of December 2013. Beyond that, I am not so certain. Merck does not want to pay penalties to PSS for terminating the contract prematurely.
 






I wouldn't be shocked if this information were true. We are losing avelox and nasonex is in third position. This does not look good for us. I wonder how long we have?
 












Anonymous said:
Hi, I was the person who posted the reply last night. According to my sources, the contract is secure to the end of December 2013. Beyond that, I am not so certain. Merck does not want to pay penalties to PSS for terminating the contract prematurely.
Click to expand...

The contract was resigned thru dec 2014 so what you are saying is that it will or could end one year early? How much notice do you think they will give us?
 






Anonymous said:
Hi, I was the person who posted the reply last night. According to my sources, the contract is secure to the end of December 2013. Beyond that, I am not so certain. Merck does not want to pay penalties to PSS for terminating the contract prematurely.
Click to expand...

Again, thanks for your response. You really did confirm what I suspected all along. I believe Merck did not expect the denial of two of their drugs by the FDA. Also with the Opthamology and Neurology departments being disolved, there is a lot of displacements. Merck is only trying to figure out if it is more cost effective to pay the penalty and cut their losses, or keep us until December 2014.
 












We are only promoting 3 products now too. We have always had 4 in our bag. This does not look good. All the signs are pointing in the wrong direction. Time to polish the resume.
 












Merck wants to keep the contract sales force. But Merck is under increasing pressure not to lay off more in the field (2 drugs denied approval by the FDA/opthalmology and neuro divisions already gone). The end result of all this is that the EPBU is now basically a redundant salesforce in addition to port A & B reps in primary care. There's only so much chairs to sit on and too many people. It want intended to end up like this, but it has unfortunately. So EPBU reps...take note...
 






Anonymous said:
Merck wants to keep the contract sales force. But Merck is under increasing pressure not to lay off more in the field (2 drugs denied approval by the FDA/opthalmology and neuro divisions already gone). The end result of all this is that the EPBU is now basically a redundant salesforce in addition to port A & B reps in primary care. There's only so much chairs to sit on and too many people. It want intended to end up like this, but it has unfortunately. So EPBU reps...take note...
Click to expand...

Do you think it will go until dec 2014 or end this year?
 






OP here, I believe if Merck decides to cut their losses, it will end Dec 2013. I was on the original Schering contract when S/P and Merck merged, we were told April 2009 that the contract would end that June (the contract had been extended until Dec 2009). I'm not sure if Merck will be that gracious. Especially since it will be around the Holidays.
 




































Top Bottom
Back
Quote